Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial [Original Articles]

Conclusions— Patients with LVSD (with/without HF) had a higher risk of SSE or death (but similar rate of SSE) compared with patients with HF but preserved LV systolic function; both had a greater risk than patients without either HF or LVSD. Apixaban reduced the risk of both outcomes more than warfarin in all 3 patient groups. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.

http://circheartfailure.ahajournals.org/cgi/content/short/6/3/451?rss=1

Source: Circulation: Heart Failure - May 21, 2013 Category: Cardiology Authors: McMurray, J. J. V., Ezekowitz, J. A., Lewis, B. S., Gersh, B. J., van Diepen, S., Amerena, J., Bartunek, J., Commerford, P., Oh, B.-H., Harjola, V.-P., Al-Khatib, S. M., Hanna, M., Alexander, J. H., Lopes, R. D., Wojdyla, D. M., Wallentin, L., Granger, C. Tags: Congestive, Cerebrovascular disease/stroke, Arrhythmias, clinical electrophysiology, drugs, Embolic stroke Original Articles Source Type: research